Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 2, 2007, Pages

  Galili, Offer ^a   Versari, Daniele ^a   Sattler, Katherine J ^a   Olson, Monica L ^a   Mannheim, Dallit ^a   McConnell, Joseph P ^a   Chade, Alejandro R ^a   Lerman, Lilach O ^a   Lerman, Amir ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

Endothelium; Leptin; Permeability; Vasodilation

Indexed keywords

3 NITROTYROSINE; LEPTIN; LYSOPHOSPHATIDYLCHOLINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ABDOMINAL WALL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD VESSEL PERMEABILITY; CALORIE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DIETARY INTAKE; ELECTRON BEAM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; EPICARDIUM; EVALUATION; FEMALE; HYPERTENSION; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; NONHUMAN; OBESITY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SWINE; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CAPILLARY PERMEABILITY; CORONARY VESSELS; DIETARY FATS; DINOPROST; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HYPERTENSION; INTRA-ABDOMINAL FAT; LEPTIN; LIPIDS; MICROCIRCULATION; NITRIC OXIDE; OBESITY; OXIDATIVE STRESS; RANDOM ALLOCATION; SUPEROXIDES; SWINE; TOMOGRAPHY, X-RAY COMPUTED; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 33847007713     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00628.2006     Document Type: Article

References (59)

1. Al Suwaidi J, Higano ST, Holmes DR Jr, Lennon R, Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37: 1523-1528, 2001.
2. Balasubramaniyan V, Nalini N. Intraperitoneal leptin regulates lipid metabolism in ethanol supplemented Mus musculas heart. Life Sci 78: 831-837, 2006.
3. Beltowski J, Wojcicka G, Marciniak A, Jamroz A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci 74: 2987-3000, 2004.
4. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 101: 2206-2212, 2000.
5. Best PJ, Lerman LO, Romero JC, Richardson D, Holmes DRJ, Lerman A. Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro. Arterioscler Thromb Vasc Biol 19: 2769-2775, 1999.
6. Bonetti PO, Best PJM, Rodriguez-Porcel M, Holmes J, David R, Lerman LO, Lerman A. Endothelin type A receptor antagonism restores myocardial perfusion response to adenosine in experimental hypercholesterolemia. Atherosclerosis 168: 367-373, 2003.
7. Bonow RO, Eckel RH. Diet, obesity, and cardiovascular risk. N Engl J Med 348: 2057-2058, 2003.
8. Brook RD, Bard RL, Rubenfire M, Ridker PM, Rajagopalan S. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 88: 1264-1269, 2001.
9. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11: 1278-1289, 2003.
10. Cersosimo E, Defronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 22: 423-436, 2006.
11. 1 receptor blockade improves renal perfusion in hypercholesterolemia. Am J Hypertens 16: 111-115, 2003.
12. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Carlo JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295, 1996.
13. De Kreutzenberg SV, Crepaldi C, Marchetto S, Calo L, Tiengo A, Del Prato S, Avogaro A. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. J Clin Endocrinol Metab 85: 793-798, 2000.
14. Eisenmann JC, Wickel EE, Welk GJ, Blair SN. Relationship between adolescent fitness and fatness and cardiovascular disease risk factors in adulthood: the Aerobics Center Longitudinal Study (ACLS). Am Heart J 149: 46-53, 2005.
15. Fornoni A, Raij L. Metabolic syndrome and endothelial dysfunction. Curr Hypertens Rep 7: 88-95, 2005.
16. Freeman JE, Kuo WY, Drenger B, Barnett TN, Levine MA, Flavahan NA. Analysis of lysophophatidylcholine-induced endothelial dysfunction. J Cardiovasc Pharmacol 28: 345-352, 1996.
17. Froese DE, McMaster J, Man RY, Choy PC, Kroeger EA. Inhibition of endothelium-dependent vascular relaxation by lysophosphatidylcholine: impact of lysophosphatidylcholine on mechanisms involving endothelium-derived nitric oxide and endothelium derived hyperpolarizing factor. Mol Cell Biochem 197: 1-6, 1999.
18. Glomset JA. The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase. Biochim Biophys Acta 65: 128-135, 1962.
19. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 9: 155-167, 1968.
20. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, and Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41: 1769-1775, 2003.
21. Greco A, Minghetti L, Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 25: 1357-1364, 2000.
22. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 21: 1-6, 2006.
23. Gunnett CA, Lund DD, Chu Y, Brooks RM 2nd, Faraci FM, Heistad DD. NO-dependent vasorelaxation is impaired after gene transfer of inducible NO-synthase. Arterioscler Thromb Vasc Biol 21: 1281-1287, 2001.
24. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 14: 103S-115S, 2001.
25. Huang F, Subbaiah PV, Holian O, Zhang J, Johnson A, Gertzberg N, Lum H. Lysophosphatidylcholine increases endothelial permeability: role of PKĆ and RhoA cross talk. Am J Physiol Lung Cell Mol Physiol 289: L176-L185, 2005.
26. i signaling. J Biomed Sci 9: 327-333, 2002.
27. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745-E751, 2001.
28. Knudson JD, Dincer UD, Zhang C, Swafford AN Jr, Koshida R, Picchi A, Focardi M, Dick GM, and Tune JD. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol 289: H48-H56, 2005.
29. 2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 12: RA5-RA16, 2006.
30. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 111: 363-368, 2005.
31. Lerman LO, Siripornpitak S, Maffei NL, Sheedy PF 2nd, Ritman EL. Measurement of in vivo myocardial microcirculatory function with electron beam CT. J Comput Assist Tomogr 23: 390-398, 1999.
32. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens 17: 1949-1953, 1999.
33. Naderali EK, Pickavance LC, Wilding JP, Williams G. Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. Clin Sci (Lond) 100: 635-641, 2001.
34. Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 54: 1082-1089, 2005.
35. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 110: 1507-1512, 2004.
36. Qiao J, Huang F, Naikawadi RP, Kim KS, Said T, Lum H. Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am J Physiol Lung Cell Mol Physiol 291: L91-L101, 2006.
37. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 33: 283-303, 2004.
38. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
39. Rodriguez-Porcel M, Krier JD, Lerman A, Sheedy PF 2nd, Romero JC, Napoli C, Lerman LO. Combination of hypercholesterolemia and hypertension augments renal function abnormalities. Hypertension 37: 774-780, 2001.
40. Rodriguez-Porcel M, Lerman LO, Herrmann J, Sawamura T, Napoli C, Lerman A. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol 23: 885-891, 2003.
41. Safaya R, Chai H, Kougias P, Lin P, Lumsden A, Yao Q, Chen C. Effect of lysophosphatidylcholine on vasomotor functions of porcine coronary arteries. J Surg Res 126: 182-188, 2005.
42. Schutte R, Huisman HW, Schutte AE, Malan NT. Leptin is independently associated with systolic blood pressure, pulse pressure and arterial compliance in hypertensive African women with increased adiposity: the POWIRS study. J Hum Hypertens 19: 535-541, 2005.
43. Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE, Berger PB, Somers VK. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109: 2181-2185, 2004.
44. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 31: 409-414, 1998.
45. Shen W, Wang Z, Punyanita M, Lei J, Sinav A, Kral JG, Imielinska C, Ross R, Heymsfield SB. Adipose tissue quantification by imaging methods: a proposed classification. Obes Res 11: 5-16, 2003.
46. Snell-Bergeon JK, Hokanson JE, Kinney GL, Dabelea D, Ehrlich J, Eckel RH, Ogden L, Rewers M. Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium. Int J Obes Relat Metab Disord 28: 1594-1599, 2004.
47. Soccio M, Toniato E, Evangelista V, Carluccio M, De Caterina R. Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. Eur J Clin Invest 35: 305-314, 2005.
48. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97: 2601-2610, 1996.
49. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA 286: 2845-2848, 2001.
50. Suda O, Smith LA, d'Uscio LV, Peterson TE, Katusic ZS. In vivo expression of recombinant vascular endothelial growth factor in rabbit carotid artery increases production of superoxide anion. Arterioscler Thromb Vasc Biol 25: 506-511, 2005.
51. Sutherland WH, Temple WA, Nye ER, Herbison PG. Lecithin: cholesterol acyltransferase activity, plasma and lipoprotein lipids and obesity in men and women. Atherosclerosis 34: 319-327, 1979.
52. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948-954, 2000.
53. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 107: 2805-2809, 2003.
54. Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 8: 337-341, 2000.
55. Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int 52: 1042-1046, 1997.
56. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350: 2362-2374, 2004.
57. Woo KS, Chook P, Yu CW, Sung RY, Qiao M, Leung SS, Lam CW, Metreweli C, Celermajer DS. Effects of diet and exercise on obesity-related vascular dysfunction in children. Circulation 109: 1981-1986, 2004.
58. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003.
59. Yan S, Chai H, Wang H, Yang H, Nan B, Yao Q, Chen C. Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells. Surgery 138: 464-473, 2005.